LIT-001

LIT-001
Clinical data
Other names	LIT001
Drug class	Oxytocin receptor agonist
Identifiers
	IUPAC name (2S)-2-(dimethylcarbamothioyl)-N-[[2-methyl-4-(1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)phenyl]methyl]pyrrolidine-1-carboxamide;
CAS Number	2245072-20-0;
PubChem CID	145711714;
ChemSpider	77006318;
UNII	Y6596259AE;
ChEMBL	ChEMBL4204210;
Chemical and physical data
Formula	C28H33N7O2S
Molar mass	531.68 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)C(=O)N2CC3=C(NC4=CC=CC=C42)N(N=C3)C)CNC(=O)N5CCC[C@H]5C(=S)N(C)C;
	InChI InChI=1S/C28H33N7O2S/c1-18-14-19(11-12-20(18)15-29-28(37)34-13-7-10-24(34)27(38)32(2)3)26(36)35-17-21-16-30-33(4)25(21)31-22-8-5-6-9-23(22)35/h5-6,8-9,11-12,14,16,24,31H,7,10,13,15,17H2,1-4H3,(H,29,37)/t24-/m0/s1; Key:AOPORIRPXVMWSL-DEOSSOPVSA-N;

LIT-001 is a small-molecule oxytocin receptor agonist and vasopressin receptor mixed agonist and antagonist that was first described in the literature in 2018. Along with TC OT 39 and WAY-267464, it is one of the first small-molecule oxytocin receptor agonists to have been developed. LIT-001 has greatly improved pharmacokinetic properties relative to oxytocin, reduces social deficits in animal models, and may have potential use in the treatment of social disorders like autism in humans. It is or was undergoing formal clinical development for such uses.